


PRODUCT: Odanacatib

ALTERNATE NAMES: MK0822; MK-0822; MK 0822; (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethyl)amino)pentanamide; cathepsin K Inhibitor

CATALOG #: B1617-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₅H₂₇F₄N₃O₃S

MOLECULAR WEIGHT: 525.56

CAS NUMBER: 603139-19-1

APPEARANCE: White solid powder

SOLUBILITY: DMSO

PURITY: >98% HPLC

STORAGE: Store at -20°C. Protect from air and light

DESCRIPTION: Odanacatib, also known as MK-0822, is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:
1: Chapurlat RD. Treatment of postmenopausal osteoporosis with odanacatib. Expert Opin Pharmacother. 2014 Jan 24.
2: Odanacatib, a cathepsin K inhibitor, superior to alendronate. Bonekey Rep. 2013 Sep 4;2:426.

RELATED PRODUCTS:

- Balicatib (# 2496)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**